Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
About this study
The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last up to approximately 156 weeks, excluding screening.
- Condition
- Alzheimer Disease
- Tested
- Donanemab, Placebo
- Sponsor
- Eli Lilly and Company
Who can join
- Age
- 55 to 80 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 12
- Minimum age: 55 years
- Maximum age: 80 years
- Study condition: Alzheimer Disease
- A Telephone Interview for Cognitive Status - Modified (TICS-M) score indicative of intact cognitive function (cut-off score of 35 or higher)
- Clinical Dementia Rating-Global Score (CDR-GS) of 0
- A plasma P-tau result consistent with amyloid pathology
- A reliable study partner who:
- Provides written informed consent to participate in the study in their role
- Has frequent contact with the participant and is familiar with their overall function and behavior, including daily activities and cognitive abilities
- Is of legal age (18 years of age or older) to consent
- Is available to conduct functional scales
- Have adequate literacy, vision, and hearing for neuropsychological testing
Exclusion 6
- Have mild cognitive impairment (MCI), dementia, or other significant neurodegenerative diseases that could affect cognition
- Have a serious or unstable illness (including cardiovascular, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease, or other condition) that, in the investigator's opinion, could interfere with study analyses or result in a life expectancy of 5 years or fewer
- Have received active or passive immunization against amyloid beta (Aβ) in any other study
- Have current or prior use of prescription medications for treatment of MCI or AD
- Have any contraindications for magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants or other accessory medical devices, such as cardiac pacemakers, stents, and cochlear implants
- Have a centrally read magnetic resonance imaging (MRI) demonstrating the presence of Amyloid-related imaging abnormalities (ARIA-E), more than 4 cerebral microhemorrhages, more than 1 area of cortical superficial siderosis, any macrohemorrhage (that is, intracerebral hemorrhage more than 1 cm), or severe white matter disease at screening
Where
30 sites, 30 recruiting
Peking University Third Hospital
Beijing, China
The First Hospital of Jilin University
Changchun, China
Xiangya Hospital Central South University
Changsha, China
Sichuan Provincial People's Hospital
Chengdu, China
2nd Affiliated Hospital Chongqing Medical University
Chongqing, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
and 24 more sites on ClinicalTrials.gov
Contact
-
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559 LillyTrials@Lilly.com
-
Physicians interested in becoming principal investigators please contact
Potential match only. Final eligibility is determined by the study team.